การวิเคราะห์ต้นทุนการรักษาด้วยการปลูกถ่ายเซลล์ต้นกำเนิดเม็ดโลหิตของตนเอง สำหรับ Lymphoma และ Myeloma

Nilawan Upakdee; Athichapan   Yoochuea; Wasee Lertkajornsin; Peerapon Wong

doi:10.33165/rmj.2024.47.1.266431

Authors

Nilawan Upakdee Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
Athichapan Yoochuea Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
Wasee Lertkajornsin Health Insurance Unit, Department of Health Service Support, Naresuan University Hospital, Phitsanulok, Thailand
Peerapon Wong Bone Marrow Transplant Unit, Naresuan University Hospital, Phitsanulok, Thailand

DOI:

https://doi.org/10.33165/rmj.2024.47.1.266431

Keywords:

Cost, Hospital charges, Autologous hematopoietic stem cell transplantation

Abstract

Background: Currently, autologous hematopoietic stem cell transplantation (HSCT) combined with high-dose chemotherapy is important for the treatment of lymphoma and myeloma.

Objective: To analyze the cost and hospital charges of autologous HSCT for lymphoma and myeloma at Naresuan University Hospital (NUH).

Methods: This was the cost descriptive study. The cost information was obtained from the primary data sources by cost data collection forms and interviews of relevant persons. Patients underwent autologous HSCT at NUH between 2009 and 2021. The charge information was collected from secondary data sources, such as the hospital database. Data was analyzed according to the treatment process 6 steps: 1) chemotherapy, 2) stem cell collection, 3) stem cell preservation, 4) high-dose chemotherapy, 5) recovery, and 6) follow-up care after the autologous HSCT. Descriptive statistics and one-way sensitivity analysis were performed.

Results: A total of 106 cases were 51 (48.11%) lymphoma patients and 55 (51.89%) myeloma patients. The cost of autologous HSCT for lymphoma and myeloma patients was ฿400,863.84 and ฿197,862.08, respectively. According to the sensitivity analysis, autologous HSCT costs ranged from ฿298,467.09 - ฿518,968.75 for lymphoma patients and ฿136,065.67 - ฿275,366.63 for myeloma patients. Medical care charges for lymphoma and myeloma were ฿359,391.74 (SD ฿143,935.92) and ฿162,763.56 (SD ฿48,649.74), respectively.

Conclusions: The cost of autologous HSCT was within the per capita budget allocation.

References

Lektrakul Y. Outcome of stem cell transplantation from low resources set up bone marrow transplantation unit. Journal of Department of Health Service Support. 2017;13(2):50-57.

Pakakasama S, ed. Hematopoietic Stem Cell Transplantation. 2nd ed. Nextstep D-Sign & Print; 2015. Accessed November 21, 2023. https://www.rama.mahidol.ac.th/cancer_center/sites/default/files/public/pdf/Article/BMT.pdf

National Health Security Office. National Health Security Fund Administration Manual, Fiscal Year 2021. Sahamitr printing & Publishing company limited; 2020. Accessed November 21, 2023. https://www.nhso.go.th/storage/files/shares/PDF/fund_man01.pdf

Comptroller General Department, Ministry of Finance. Welfare Guide for Civil Servants Medical Benefit Handbook. Accessed November 21, 2023. https://dmsic.moph.go.th/index/detail/8352

Wong P, Deoisares R, Tapprom A, et al. Treatment outcomes of high dose chemotherapy and autologous hematopoietic stem cell transplantation for lymphoma and myeloma in a regional hospital. J Hematol Transfus Med. 2015;25(2):123-129.

Sanpakit K, Tabjareon S, Akaniroj S, Torsuwan N, Veerakul G. Analysis of hospital charges for hematopoietic stem cell transplantation in pediatric patients during admission at Siriraj Hospital. J Hematol Transfus Med. 2010;20(2):127-134.

Chen M, Liu Y, Yang X, Hong Y, Ni J. Cost analysis of childhood hematopoietic stem cell transplantation in Sichuan, China. Front Public Health. 2023;11:990181. doi:10.3389/fpubh.2023.990181 DOI: https://doi.org/10.3389/fpubh.2023.990181

Rivera-Franco MM, Leon-Rodriguez E, Castro-Saldaña HL. Costs of hematopoietic stem cell transplantation in a developing country. Int J Hematol. 2017;106(4):573-580. doi:10.1007/s12185-017-2278-1 DOI: https://doi.org/10.1007/s12185-017-2278-1

Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000;18(1):64-71. doi:10.1200/JCO.2000.18.1.64 DOI: https://doi.org/10.1200/JCO.2000.18.1.64

Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin’s and non-Hodgkin’s lymphoma. J Clin Oncol. 1997;15(1):5-10. doi:10.1200/JCO.1997.15.1.5 DOI: https://doi.org/10.1200/JCO.1997.15.1.5